Genomic Health (GHDX) Reports In-Line Q2 EPS
Get Alerts GHDX Hot Sheet
Join SI Premium – FREE
Genomic Health (NASDAQ: GHDX) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $82 million versus the consensus estimate of $81.27 million.
GUIDANCE:
Genomic Health sees FY2016 EPS of ($0.37)-($0.55), versus the consensus of ($0.45). Genomic Health sees FY2016 revenue of $325-335 million, versus prior guidance of $320-335 million and the consensus of $330.5 million.
For earnings history and earnings-related data on Genomic Health (GHDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Planet Labs (PL) Reports In-Line Q4 EPS, provides guidance
- Oxford Industries (OXM) Reports In-Line Q4 EPS, provides guidance
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!